FibroBiologics Announces 2025 Annual Meeting of Stockholders
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced its 2025 Annual Meeting of Stockholders, scheduled for June 12, 2025, at 11 a.m. CDT. The meeting will be held exclusively in a virtual format.
The company, which focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has set April 14, 2025 as the record date for stockholder voting eligibility. FibroBiologics currently maintains a portfolio of 160+ US and international patents/patents pending across various clinical pathways, including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Reversing organ involution
- Cancer
Positive
- Portfolio of 160+ US and international patents/patents pending across multiple therapeutic areas
Negative
- None.
News Market Reaction – FBLG
On the day this news was published, FBLG declined 1.92%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) 2025 Annual Stockholders Meeting?
What is the record date for voting eligibility at FBLG's 2025 Annual Meeting?
How many patents does FibroBiologics (FBLG) currently hold?
What medical conditions is FibroBiologics (FBLG) developing treatments for?
